Loading...
XNAS
AXGN
Market cap2.33bUSD
Jul 09, Last price  
43.62USD
1D
2.04%
1Q
36.48%
Jan 2017
384.67%
Name

AxoGen Inc

Chart & Performance

D1W1MN
XNAS:AXGN chart
P/E
P/S
10.30
EPS
Div Yield, %
Shrs. gr., 5y
2.87%
Rev. gr., 5y
14.93%
Revenues
225m
+20.21%
126,660100,43172,71124,911,37691,2734,849,4707,691,70410,947,36116,817,40327,331,09241,107,53860,426,39583,937,000106,712,000112,300,000127,358,000138,584,000159,012,000187,338,000225,208,000
Net income
-16m
L+57.60%
-367,182-748,980-1,040,70915,046,332-1,316,299-9,219,220-9,417,958-14,556,885-17,710,476-13,356,425-14,411,144-10,445,462-22,397,000-29,122,000-23,786,000-26,985,000-28,948,000-21,716,000-9,964,000-15,703,000
CFO
812k
-82.09%
-28,793-466,947-470,16415,441,941-2,429,661-7,079,290-8,661,858-10,444,758-10,451,059-13,051,819-11,204,442-9,237,599-17,862,000-19,872,000-9,626,000-13,405,000-16,066,000-5,716,0004,535,000812,000
Dividend
Jan 27, 20101 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
IPO date
Dec 17, 1986
Employees
394
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT